医学
化疗
卡铂
培美曲塞
内科学
肿瘤科
化疗方案
肺癌
危险系数
奥西默替尼
无进展生存期
临床研究阶段
养生
癌症
顺铂
埃罗替尼
表皮生长因子受体
置信区间
作者
Antonio Passaro,Jing Wang,Yan Wang,S.-H. Lee,Barbara Melosky,Jin‐Yuan Shih,Jing Wang,K. Azuma,Óscar Juan,Manuel Cobo,Enriqueta Felip,Nicolas Girard,Alexis B. Cortot,Raffaele Califano,Federico Cappuzzo,Scott Owen,Sanjay Popat,Ju Le Tan,Jorge Salinas,Pascale Tomasini
标识
DOI:10.1016/j.annonc.2023.10.117
摘要
Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved PFS and intracranial PFS versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen.
科研通智能强力驱动
Strongly Powered by AbleSci AI